| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9267626 | Joint Bone Spine | 2005 | 6 Pages |
Abstract
Conclusions. - The powerful advertisement campaigns that surrounded the introduction of COX2 inhibitors rapidly affected practice patterns regarding the prescription of antiinflammatory drugs. The study reported here showed a significantly greater likelihood of receiving COX2 inhibitors in older patients taking multiple medications, a population known to be at increased risk for drug-induced cardiovascular events. Evidence obtained after the present study established that COX2 inhibitors carry a risk of cardiovascular side effects. Rofecoxib has been removed from the market, and new recommendations have been issued regarding other COX2 inhibitors.
Related Topics
Health Sciences
Medicine and Dentistry
Immunology, Allergology and Rheumatology
Authors
Martine Modica, Philippe Vanhems, Jacques Tebib,